Morgan Stanley assumed coverage of BioMarin (BMRN) with an Overweight rating with a price target of $97, down from $105. BioMarin is trading at a 10-year low, more than adequately reflecting risk to its Voxzogo franchise, the analyst says. Morgan Stanley believes the potential opportunity in other patient populations and the company’s pipeline may be underappreciated by the Street.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- Positive Outlook for BioMarin Pharmaceutical Amid Competitive Challenges and Market Expansion Opportunities
- BioMarin Pharmaceutical’s Growth Potential and Competitive Edge Amidst Market Challenges
- BioMarin reports new data underscoring the long-term efficacy of ROCTAVIAN
- BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights
- BioMarin Pharmaceutical: Navigating Competitive Challenges with Strategic Growth Potential